Sex-Specific Detection Panels Show High Accuracy for Early-Stage Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 10, 2024 -- Sex-specific cancer detection panels comprising 10 proteins show high accuracy for detecting early-stage cancers among men and women, according to a study published online Jan. 9 in BMJ Oncology.
Bogdan Budnik, Ph.D., from Novelna Inc. in Palo Alto, California, and colleagues collected plasma samples from 440 healthy individuals and individuals diagnosed with 18 early-stage solid tumors to develop a novel proteome-based multicancer screening test. More than 3,000 high- and low-abundance proteins in each sample were measured. A limited set of sex-specific proteins that could detect early-stage cancers and their tissue of origin with high accuracy was identified using a multistep statistical approach.
The researchers found that for both men and women, the sex-specific cancer detection panels consisting of 10 proteins showed high accuracy (areas under the curve, 0.98 and 0.983, respectively). The panels were able to identify 93 and 84 percent of cancers among men and women, respectively, at stage I and at a specificity of 99 percent. In more than 80 percent of cases, sex-specific localization panels consisting of 150 proteins could identify the tissue of origin of most cancers. Almost all proteins were found to be in the low-concentration part of the human plasma proteome in an analysis of the plasma concentrations of proteins selected.
"These results provide a foundation for future research and emphasize the potential of proteomic analysis in revolutionizing cancer diagnosis at the population level," the authors write.
The authors disclosed financial ties to Novelna, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.